Alzheon

Alzheon is a clinical-stage biopharmaceutical company focused on developing innovative oral treatments for Alzheimer’s disease, with its lead candidate ALZ-801 in late-stage clinical trials. The company’s business model centers on research, development, and future commercialization of precision medicine therapies targeting high-risk genetic populations, particularly APOE4 carriers. Alzheon is recognized for its pioneering approach in disease-modifying treatments for neurodegenerative disorders.

Company Facts

• Headquarters: Framingham, United States
• Founded: 2013
• Employees: 30
• Type: Private Company
• Website: https://alzheon.com
• Industries: Biotechnology, Pharmaceuticals, Healthcare, Precision Medicine